Clinical Trial Update: Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial (SAPHIRE) is evaluating adding sapanisertib to cabozantinib for advanced or metastatic hepatocellular carcinoma with β-catenin gene a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Sapanisertib (sapanisertib)
• cabozantinib (cabozantinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma | Phase 1, Phase 2 | Status: RECRUITING